Abstract
We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p <.001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 573-584 |
| Number of pages | 12 |
| Journal | Cancer Investigation |
| Volume | 29 |
| Issue number | 9 |
| DOIs | |
| State | Published - Nov 2011 |
Fingerprint
Keywords
- Breast cancers
- Chemotherapy
- Outcomes research
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. / Griffiths, Robert I.; Lalla, Deepa; Herbert, Robert J.; Doan, Justin F.; Brammer, Melissa G.; Danese, Mark D.
In: Cancer Investigation, Vol. 29, No. 9, 11.2011, p. 573-584.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab
AU - Griffiths, Robert I.
AU - Lalla, Deepa
AU - Herbert, Robert J.
AU - Doan, Justin F.
AU - Brammer, Melissa G.
AU - Danese, Mark D.
PY - 2011/11
Y1 - 2011/11
N2 - We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p <.001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.
AB - We used Surveillance, Epidemiology, and End ResultsMedicare data (2000-2006) to describe treatment and survival in women diagnosed with metastatic breast cancer (MBC) who received trastuzumab. There were 610 patients with a mean age of 74 years. Overall, 32% received trastuzumab alone and 47% received trastuzumab plus a taxane. In multivariate analysis, trastuzumab plus chemotherapy was associated with a lower adjusted cancer mortality rate (Hazard Ratio [HRé 0.54; 95% Confidence Interval [CIé 0.39-0.74; p <.001) than trastuzumab alone among patients who received trastuzumab as part of first-line therapy. Adding chemotherapy to first-line trastuzumab for metastatic breast cancer is associated with improved cancer survival.
KW - Breast cancers
KW - Chemotherapy
KW - Outcomes research
UR - http://www.scopus.com/inward/record.url?scp=80054859025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054859025&partnerID=8YFLogxK
U2 - 10.3109/07357907.2011.616251
DO - 10.3109/07357907.2011.616251
M3 - Article
C2 - 21929325
AN - SCOPUS:80054859025
VL - 29
SP - 573
EP - 584
JO - Cancer Investigation
JF - Cancer Investigation
SN - 0735-7907
IS - 9
ER -